Slide 1: Q4/FY'22 Financial Results Conference Call
Q4/FY’22 Financial Results Conference Call NASDAQ & TASE: KMDA March 15, 2023
Slide 2: Forward Looking Statement
FORWARD LOOKING STATEMENT This presentation is not intended to provide investment or medical advice . It should be noted that some products under development described herein have not been found safe or effective by any regulatory agency and are not approved for any use outside of clinical trials .
Slide 3: Kamada Highlights
6 FDA approved products ; global commercial network selling in over 30 countries 2023 revenue guidance of $138M - $146M; EBITDA of $22M - $26M; rapidly growing; positive cash flow; compelling financial profile Multiple growth drivers with significant upside potential and limited downside ri sk KAMAD
Slide 4: Financial Growth Trajectory
FINANCIAL GROWTH TRAJECTORY Adjusted EBITDA is defined as net income, plus (i) tax expense, (ii) financial income (expense), net, (iii) depreciation and amortization ; and (v) non - cash share - based compensation expenses 4 Kamada / March 2023 Strategic acquisition & multiple catalysts drove 2022 f
Slide 5: Significant Catalysts Driving Double Digit Growth
SIGNIFICANT CATALYSTS DRIVING DOUBLE DIGIT GROWTH 5 Kamada / March 2023 CYTOGAM (~$23M FY22) & KEDRAB (~$16M FY22) significant growth in the U.S. @ over 50% GM Glassia royalties $10M - $20M/year through 2040 (~$12M FY22) Glassia ex - U.S. (~$6M FY22) @ 40% GM Israeli distribution growth, including l
Slide 6: FDA-Approved Speciality Plasma Products; Key Focus on Transplantation & Rare Conditions
FDA - APPROVED S PECIALITY PLASMA PRODUCTS; KEY FOCUS ON TRANSPLANTATION & RARE CONDITIONS 6 Kamada / March 2023 CYTOGAM® [Cytomegalovirus Immune Globulin Intravenous (Human)] Prophylaxis of cytomegalovirus disease associated with transplantation KEDRAB/KAMRAB® [Rabies Immune Globulin (Human)] Post
Slide 7: Strategic Entry into the U.S. Plasma Collection Market
STRATEGIC ENTRY INTO THE U.S. PLASMA COLLECTION MARKET Kamada Plasma was established in Q 1 20 21 through the acquisition of an FDA - licensed plasma collection center in Texas ; focus ed on collecting hyper - immune plasma for specialty IgG ’ s o Strategic transaction which advances Kamada ’ s obje
Slide 8: Inhaled AAT Anticipated Benefits
• Non - invasive, at - home treatment. Expected better ease of use and quality of life for AATD patients than current IV standard of care • Most effective mode of treatment for delivering therapeutic amounts of AAT directly into the airways • Studied in more than 200 individuals to date, with an est
Slide 9: Kamada Investment Highlights
KAMADA INVESTMENT HIGHLIGHTS 9 Kamada / March 2023 A global leader; focused on areas of limited treatment alternatives Financially attractive ; profitable; cash - generating; continued double digit growth 6 FDA approved products with significant worldwide growth potential Leading innovative product
Slide 10: Summary Financial Data
SUMMARY FINANCIAL DATA Adjusted EBITDA is defined as net income, plus (i) tax expense, (ii) financial income (expense), net, (iii) depreciation and amortization ; and (v) non - cash share - based compensation expenses US $ M 20 21 2022 Details PROPRIETARY 76 103 36% YoY increase DISTRIBUTION 28 27 T
Slide 11: Thank You
March 15, 202 3 THANK YOU WWW.KAMADA.COM